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We have demonstrated expression of a 6.3 kb Becker muscular dystrophy (BMD) haman dystrophin cDNA following retroviral-mediated 
transduction of cultured myoblasts from the dystrophin-deficient rod.x" mouse. The truncated ystrophin protein was localiscd to the sarcolcmma 
of differentiated myotube5 by antibodies against he C.terminus el'the molecule, and produced an identical immunostaining pattern o that observed 
in control myotubes xpressing normal endogenous dystrophin. These results indicate that retroviral-mediated gene transl'er may be useful for 
exl~rimental in rive studies on the complementation f dystrophin gone mutations, 
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1. INTRODUCTION 
Duchenne Muscular Dystrophy (DMD) is a reces- 
sive, X-linked condition caused by nonsense mutations 
or complete deletion of the gene for dystrophin, a large 
(mol. wt. 427 kDa) cytoskeletal protein most abundant 
in skeletal muscle [1]. It affects 1 in 3500 males leading 
to progressive muscular weakness and death usually in 
the third decade [2]. 
The rod?: mouse is an animal model ot" DMD, lacking 
dystrophin expression in all but a very small percentage 
of myofibres [1,3] due to a point mutation in the mouse 
homologue ot" the DMD gone [4]. Although severe 
dystrophic changes are observed in the muscles of the 
diaphragm [5], the mdx mouse does not show the pro- 
gressive degeneration of limb muscles characteristic of 
the human disease. Instead, a high level of myofibre 
regeneration in the limbs seems to effectively restore 
muscle integrity and function [6]. Nevertheless, mdx 
mouse skeletal muscle provides an excellent model for 
the early myopathic phase of DMD. 
Recently, retroviral vectors have been widely used for 
the efficient, stable introduction of foreign genes into 
eukaryotic cells in vitro and in rive [7-1 l]. The 14 kb 
full-length eDNA of the DMD gone [12], however, ex- 
ceeds the 10-12 kb packaging limit ot" retroviruses. 
Therefore, a 6.3 kb dystrophin minigene eDNA derived 
from a patient with very mild Booker Muscular 
Dystrophy (BMD)[13] has been incorporated into the 
MoMuLV-based retroviral vector, pBabe Nee [14]. 
This minigene expresses a truncated protein lacking 
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over 40% of the central rod domain of the normal dys- 
trophin molecule, yet the patient suffers very little func- 
tional loss. Transduction of the retroviral minigene con- 
struct into mdx mouse myoblasts in vitro lead to the 
expression of a truncated dystrophin protein at the sar- 
colemma of differentiated myotttbes. 
2. MATERIALS AND METHODS 
2,1 Construction of the retroviral pta.~'mid, pl~Nl 
The 6.3 kb dystrophin eDNA [15] was inserted into the Sail site of 
the retroviral vector pBabe Nee to yield an 11.5 kb construct, pBN 1 
(Fif~. 1). Constitutive transcription of the eDNA insert is driven fi.ot-a 
the Moloney murine l ukaemia virus promoter in the 5' LTR and 
polyadcnylated from the 3' LTR of the provirus, An internal SV40 
early promoter drives transcription of the nee gene which confers 
resistance to the aminoglycoside G418 in mammalian el ls  and hana- 
mycin sulphate in bacteria. The vector can be packaged into infectious 
retrovirus particles in combination with the packaging cell line,/'2E 
[141, 
2.2. Transfections, cell littes and determit~atiotr oJ" viral titres 
Transient transfeetions f COS cells and the ecotropic helper.free 
packaging cell line, DE were performed with plasmids pBabeNeo and 
pBNI by DNA/calcium phosphate precipitation [16], Supernatants 
containing transiently.produced r combinant retrovirus from trans- 
fected ~E cells were used to infect OE cells treated with 30 ng/ml 
tunicamycin (Sigma) as prevlously described [17] in order to achieve 
stable integration of the proviral DNA into the genome. Drug resis- 
tant colonies were selected in Dulbce¢o'~ modified Eagle's medium 
(DMEM) containing 10% (v/v) foetal calf serum and 500/ag/ml G418 
(Geneticin, Gibco). Stable producer cell lines manufacturing retrovi- 
rus at the highest itre were selected following infection-~ssay of NIH- 
3T3 cells. The volume of media in 100 man dishe~ of subc,~nfiuent 
producers wa~ reduced to 5 ml, harvested 72 h later and filtered 
through 0.45/am filter. Serial dilutions were made in 2 ml of medium 
(DMEM; 10% FCS) containing 8 /ag/ml polybrcne (Sigma) and 
applied to 7.5 x 10 ~ NIH3T3 ceils on 100 mm dishes for 4 h. The 
following day. cells were split at a ratio of 1:20 in medium containing 
500/.¢g/ml G418 and incubated until drug resistant colonle~ were 
clearly visible. 
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2,3, Retro~,iral infection OJ'lwimao' cultures 
Muscle tissue was dissected from the hind limbs of 3-6.week-old 
control C57/B10 and dystrophin.deficient mdx mice and dissociated 
for primary culture ssentially as described [18], Dissociated cells were 
preplated on uncoated plastic tissue culture dishes for 30 rain to 
remove fibroblasts prior to plating onto glass coverslips or 35 mm 
tissue culture dishes coated with 25 pg/ml poly-L-lysine and 8/Jg/ml 
laminin (Sigma) [19]. Three days later, eovcrslips and 35 trim dishes 
were transferred to 16 mm wells or 100 mm tissue culture dishes 
previously plated with control or minigene producer c¢11 lines (con- 
taining integrated pBabeN¢o r pBNI proviruses, respectively), and 
~rown in growth medium (DMEM; 20% FCS) containing 2/ag/ml 
polybrene, At onset of differentiation to myotubcs, the media was 
changed to DMEM containing 5% (v/v) horse serum. 
2,4. hnmttnuc:~,tochetnistry attdI Vestern blot atzatysis 
For immunostaining analyses, ceils grown on covcrslips were fixed 
in methanol (-20°C) and incubated individually or simultaneously 
with a mouse monoclonal antibody MANDYS 1 [20,21] against a 
central rod domain epitope of dystrophin and rabbit antibodies, 136 
and Gg, raised, respectively, to N- and C.terminal sytathetlc peptide 
anti~.ens of the molecule, Subsequent incubations were curried out 
with fluorescein-conjugated anti-mouse and biotinylated anti-rabbit 
antibodies, prior to tertiary labelling of the biotinylated antibody with 
streptavidin-conjugated T xas Red (Amersllam). Stained cells were 
viewed on a Zeiss microscope quipped with phase contrast and epi- 
fluorescence optics, 
3. RESULTS 
3.1. Expression o/'the Becker-type dystrophhl eDNA in 
COS cells 
Retroviral-mediated gene transfer is currently the 
most effective way of stably integrating DNA into 
mammalian genomes. Therefore a human dystrophin 
minigene was cloned into the retroviral vector pBabe 
Nee to achieve stable gene transfer in cultured mdx 
mouse skeletal muscle cells, pBabe Nee contains an 
SV40 origin of replication, enabling high level expres- 
sion of plasmid-borne cDNAs in transfected COS cells 
[22]. Thus before proceeding to isolate recombinant re- 
troviral producer" cell lines, the integrity of the Becker 
minigene construct, pBNI (Fig. 1) was confirmed by 
detection of recombinant dystrophin expression i  COS 
cells transl~eted with pBNI plasmid DNA. Incubation 
of methanol fixed COS cells with antibodies against he 
N- and C-terminal epitopes of the dystrophin molecule 
resulted in strong fluorescent labelling of the truncated 
dystrophin in pBNI, but not pBabe Neo-transfected 
cells (Fig. 2A,B). 
3.2. Production of stable, high titre producer cell lines 
Production of a high titre of recombinant retrovirus 
is necessary to achieve high efficiency gene transfer. 
Therefore, 24 stable DE producer cell lines were 
screened for infectivity against NIH 3T3 cells. Re- 
trovirus particles released by these producer cells into 
the media were referred to as RV.Babe Nee and 
RV.BN1. Average counts of G418 resistant colonies of 
NIH 3T3 cells following infection with retroviral super- 
natants were used to ealcutate retroviral titres according 
to the formula of Cepko [23], expressed as colony-form- 
ing units (cfu) per ml. The RV.BN 1 producer cell line 
of highest itre yielded an average of 4.1 x 104 cfu/ml. 
Retroviral titres were lower than reported elsewhere 
[7,24], perhaps due to less efficient packaging of such a 
large amount (10.5 kb) of proviral RNA from pBNI, 
which is close to the packaging size limit of retroviral 
capsids. 
For safety reasons, it is important to ensure that in- 
fected target cells are unable to generate replication- 
competent recombinant retrovirus which could act as 
"helper' virus and lead to uncontrolled infections [25]. 
The DE cell line adopts the strategy developed by Mar- 
kowitz et al. [26] where the genes gagpol and env, vital 
for viral replication and infection, were introduced on 
separate plasmids to prevent recombination events 
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Fig, 1. The r~troviral plasmid, pBNI, contains a 6.3 kb Becker-type dystrophin eDNA inserted into the Sail site of the retroviml vector pBab= 
Nee, This minigene lacks 5,1 kb from the central region of the 14 kb normal human dystrophin eDNA. 
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Fig. 2. Immunostaining oi" pBN l-transfe~ted COS cells with antibodies al3ainst (A) the N-terminal nd (B) C-terminal domains of the d~,strophin 
molecule. Magnification. ×600. 
leading to helper virus production. In order to test for 
helper activity, NIH 3T3 cells were incubated with the 
conditioned media from previously-infected NIH 3T3 
cells in the pre.,,ence of 8/.tg/ml polybrene. No G418- 
resistant cells were subsequently detected, validating the 
'helper-free' status of the producer cell lines. 
3.3. E.,cpression f the Becket'-type dystrophh~ eDNA in 
transduced mdx myotubes 
Recently, Hoffman et al. [3] have reported the very 
occasional (<1.0%) occurrence of mdx mouse myofibres 
which appear' to express the full-length dystrophin pro- 
tein. Therefore, dual antibody labelling of infected cul- 
tures was employed to distinguish myotubes expressing 
the dystrophin minigene from 'revertant' or 'suppressor 
mutant' fibres. Staining patterns observed using a mo- 
noclonal antibody (MANDYS t) against part of the 
dy~trophin central rod domain absent fi'om the Becker- 
type protein [13] was compared with concurrent stain- 
ing of the same samples with an antibody (Gg) against 
the C-termlnal region, common to boda full- length and 
truncated molecules. 
10-15 days after infection of primary myoblast cul- 
tures with the recombinant retrovirus, RV.BN 1, intense 
Texas-Red immunostaining with the C-terminal 
dystrophin antibody was observed at the sarcolemma of
all C57/BI0 and 5-10% of md.x myotubes (Fig. 3.) No 
C-terminal abelling was observed in md.,¢ cultures ex- 
posed to control retrovirus RV.Babe Neo alone. In con- 
trast, the rod domain antibody showed no fluorescein 
labelling of rod.x" myotubes exposed to either RV.BNI 
or RV.BabeNeo, but only at the sarcolemma of C57/ 
B10 normal mouse myotubes. No "revertant' mdx myo- 
tubes were observed. At high power magnification of 
C-terminal labelled mdx myotubes, a veined pattern and 
sarcoiemmai iocalisatioi~ of the truncated ystrophin 
could be seen that was identical to the staining pattern 
observed at the surface of normal dystrophin-positive 
130 
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myotubes [27] (Fig. 4). These results clearly demon- 
strate xpression of the Becker-type dystrophin in trans- 
duced mdx myotubes. 
4. DISCUSSION 
A number of methods have been used to achieve dy- 
strophin expression in skeletal and cardiac muscles of 
the dystrophin-deficient mdx mouse, including transfer 
ofdystrophin-positive myoblasts into regenerating skel- 
etal muscle [28], direct injection of dystrophin cDNAs 
[15] and injection of fertilised mouse ova with linearised 
DNA to produce transgenic animals (Wells et al., un- 
published). However, at present he preferred method 
of somatic gene transfer into mammalian cells is by 
means of retroviral vectors due to their high efficiency 
and stable integration of proviral DNA [24]. Despite the 
limited packaging size of retroviruses which precludes 
incorporation of the 14 kb full length DMD eDNA, we 
have shown that retroviral mediated transfer of a 
dystrophin minigene is possible and results in the 
correct localisation of the gene product at he sar- 
colemma of skeletal muscle myotubes. 
This truncated ystrophin molecule is at least semi- 
functional in vivo, as the BMD patient bearing the dele- 
ted gene remains ambulatory at 62 years of age. There- 
fore, expression of the minigene in mdx myofibres may 
correct some of the cellular defects of dystrophic mus- 
cle, such as membrane instability [29] and raised in- 
tracellular calcium levels [30]. Indeed, Aesadi et al. [15] 
have demonstrated that expression of an identical 
eDNA following its direct injection into mdx muscle in 
vivo results in a decreased number of centrally 
nucleated fibres, indicating a reduction in muscle dam- 
age and regeneration. This has been extended by Wells 
et al. (unpublished) in transgenic mice expressing the 
necker dystrophin, who also observed a significant 
reduction in the number of centrally nucleated fibres 
relative to non-transgenic mdx control animals. 
It is thought hat the presence of N- and especially 
C-terminal domains in Becker dystrophin molecules en- 
ables relatively normal interactions with components of
the eytoskeleton, such as aetin [31] and membrane- 
bound glyeoproteins [32]. This may result in tess severe 
membrane damage relative to dystrophin-deficient 
myofibres, and a consequently milder phenotype. 
Differentiated myotubes are mitotically inactive, 
favouring stable expression of introduced genes. In this 
study expression of the Becker minigene in mdx 
myotubes was still detectable 3-4 weeks post-infection 
(data not shown) and at comparable levels to normal 
myofibres (Fig. 4.). Since dystrophin transcripts are 
present at fairly low levels in normal skeletal muscle 
[33], expression of a recombinant dystrophin from a 
strong retrovirai promoter in one or two nuclei may be 
sufficient o prevent muscle necrosis when introduced 
into the post-natal animal. 
Recently, Salminen et al. [34] have used a retrovirus 
to introduce a human multi-drug reporter gene eDNA 
into cultured rat myocytes which were later implanted 
into the skeletal muscle of immunosuppressed adult 
rats. Myoblasts from biopsies of dystrophin-deficient 
animals could be transduced with recombinant dystro- 
phin retroviruses in vitro, expanded and replaced into 
the skeletal muscle of the donor without requiring im- 
munosuppression. Fusion of these recombinant 
myoblasts with dystrophic muscle may result in dys- 
trophin expression in numerous keletal muscle fibres. 
The results reported here clearly demonstrate hat a 
functional dystrophin minigene can be packaged in in- 
fectious retrovirus particles and used to stably trans- 
duce primary mdx myoblasts in vitro. The integrated 
dystrophin eDNA is expressed at high levels from the 
MoMuLV retroviral promoter leading to correct loeali- 
sation of the gene product at the sareolemma of mature 
myotubes. Furthermore, as retroviruses only infect ac- 
tively dividing ceils [35] the high mitotic activity of re- 
generating dystrophic muscle may make it a highly 
suitable target for direct retroviral-mediated ransfer of 
dystrophin genes in vivo. 
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